• About
  • Masthead
  • License Content
  • Advertise
  • Press Releases
  • Newsroom
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

Sign in
SUBSCRIBE
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • Medical Calculators
    • Clinical Guidelines
    • Physician Pay by Specialty
    • FDA Drug Approvals
    • RVU Search
    • ICD-10 Code Lookup
    • Drug Safety for Breastfeeding/Pregnancy
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
    • NPI Registry Lookup
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
2 Minute Medicine
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • Medical Calculators
    • Clinical Guidelines
    • Physician Pay by Specialty
    • FDA Drug Approvals
    • RVU Search
    • ICD-10 Code Lookup
    • Drug Safety for Breastfeeding/Pregnancy
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
    • NPI Registry Lookup
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
Sign in
SUBSCRIBE
2 Minute Medicine
Sign in
Subscribe
2 Minute MedicineFree on Google PlayGet
✦EvidencePulse™by 2 Minute Medicine3 reportsYou askedtop stroke trials 2026Synthesizing medical evidence...Top 2026 stroke trial results:OCEANIC — ischemic stroke: 6.2% vs 8.4%OPTION* — mRS 0–1: 43.6% vs 34.2%ORIENTAL* — mRS 0–2: 58.6% vs 46.6%*Higher sICH in intervention armsParticipants randomizedNOCEANIC12,327OPTION570ORIENTAL564Ask about guidelines or landmark trials...↑Try EvidencePulse™Ask the evidence. Get the signal.Try it now →
Home All Specialties Cardiology

Drug-eluting scaffold superior to angioplasty for infrapopliteal artery disease

byNhat Hung (Benjamin) LamandKiera Liblik
January 18, 2024
in Cardiology, Chronic Disease, Surgery
Reading Time: 2 mins read
Share on FacebookShare on TwitterShare on LinkedIn

1. In this randomized controlled trial, for patients with chronic limb-threatening ischemia (CLTI) due to infrapopliteal artery disease (IAD), a drug-eluting resorbable scaffold was superior to angioplasty in reducing the risk of vascular events. 

2. There was no significant difference in the adverse events between the drug-eluting resorbable scaffold and angioplasty groups. 

Evidence Rating Level: 1 (Excellent)

Study Rundown: Peripheral artery disease is an epidemic, and its incidence is increasing alongside other cardiovascular diseases. The most severe complication is CLTI, and affected patients are at high risk of amputation and death. For those with CLTI due to IAD, angioplasty demonstrated superiority to open procedures, but it is associated with limited durability. Drug-eluting resorbable scaffolds offer the advantage of mechanical support, delivery of antiproliferative agents, and resorption allowing for favorable vessel remodeling and future intervention. This study compared everolimus-eluting resorbable scaffold against angioplasty for CLTI due to IAD. At one year, the composite risk of amputation, vessel occlusion, revascularization, or restenosis was significantly lower among the scaffold group than the angioplasty group. The rates of adverse events, including major adverse limb events and perioperative death, were comparable between the two groups and demonstrated noninferiority. The study was limited by a small and specific patient sample, and the scaffold was only employed in the proximal two-thirds of the infrapopliteal arteries. Nevertheless, it supported that an everolimus-eluting resorbable scaffold was superior to conventional angioplasty in treating CLTI secondary to IAD.

Click here to read the study in the NEJM (New England Journal of Medicine)

In-Depth [randomized controlled trial]: The current study was a randomized controlled trial comparing everolimus-eluting resorbable scaffold against angioplasty in treating CLT due to IAD. Patients 18 years of age or older presenting with CLTI due to IAD, with specific anatomical criteria such as the lesions located within the proximal two-thirds of the infrapopliteal arteries and the lengths of scaffold required to treat less than 170mm, were included. Exclusion criteria included severe lesions and those outside anatomical criteria, pregnancy, recent amputation, serious kidney disease, recent stroke, and immunosuppressive diseases. Two hundred sixty-one patients were randomized 2:1 to receive an everolimus-eluting resorbable scaffold or angioplasty. The primary efficacy outcome was freedom from amputation above the ankle of the target limb, complete occlusion of the target vessel, need for revascularization, and binary restenosis of the target lesion at one year. The primary safety outcome was freedom from major adverse limb events at six months and perioperative death. Overall, the primary efficacy outcome occurred in 74% of patients in the scaffold group and 44% of the angioplasty group (absolute difference 30 percentage points; 95% Confidence Interval [CI], 15 to 46; p<0.001 for superiority). Binary restenosis occurred in 24% of patients in the scaffold group and 50% of the angioplasty group (p<0.001 for superiority). The primary safety outcome was observed in 97% of the scaffold group and 100% of the angioplasty group (absolute difference -3 percentage points; 95% CI -6 to 0; p<0.001 for noninferiority). In summary, these results demonstrated the potential advantage of drug-eluting resorbable scaffolds over angioplasty in treating CLTI due to IAD.

RELATED REPORTS

Bariatric surgery associated with lower obesity-related cancer incidence in Nordic cohort

Early mitral valve surgery may improve long-term survival in asymptomatic severe mitral regurgitation

Image: PD

©2024 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: Angioplastycardiologychronic diseaseDrug-eluting scaffoldeverolimusinfrapopliteal artery diseaselimb-threatening ischemiaSurgeryvascular surgery
Previous Post

#VisualAbstract: Oral Simnotrelvir Shortens COVID-19 Symptom Duration in Adult Patients with Mild-to-Moderate COVID-19

Next Post

#VisualAbstract: Pembrolizumab enhances progression-free survival in patients with HER2-positive gastro-esophageal cancer

RelatedReports

Comparison of two types of bariatric surgery: a sleeve gastrectomy represented by a drawn stomach outline and a gastric band represented by a stomach with a band.
Chronic Disease

Bariatric surgery associated with lower obesity-related cancer incidence in Nordic cohort

November 18, 2026
Mitral valve prolapse collage of an engraved heart with a parachute-like valve, a stethoscope and a calm woman
Cardiology

Early mitral valve surgery may improve long-term survival in asymptomatic severe mitral regurgitation

October 31, 2026
Two pieces of fabric showing stitching techniques with surgical tools in the foreground, indicating procedures for hernia repair.
Gastroenterology

Induction with remimazolam (Byfavo) for patients undergoing laparoscopic gastrointestinal surgery may reduce post-operative delirium compared with propofol

October 20, 2026
Robotic surgical instruments with surgical mesh and sutures, indicating a procedure for hernia repair.
Gastroenterology

Dexmedetomidine (Precedex) may offer similar analgesic efficacy as remifentanil (Ultiva) with fewer adverse effects in adults undergoing sleeve gastrectomy

October 6, 2026
Next Post
#VisualAbstract: Pembrolizumab enhances progression-free survival in patients with HER2-positive gastro-esophageal cancer

#VisualAbstract: Pembrolizumab enhances progression-free survival in patients with HER2-positive gastro-esophageal cancer

Risk factors associated with cognitive impairment development in older adults

Yoga and meditation collage: a rolled yoga mat, a round meditation cushion and a lotus flower on a pale pool

At-Home Eccentric Exercises Improve Functional Ability More Than Stretching in Older Women

✦ EvidencePulse™ by 2 Minute Medicine 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... Try EvidencePulse™ Get the signal. Try it now → Physician-trained medical AI by 2 Minute Medicine

2MM+ All Access

Full details →
$4.99 /month

3-day free trial · cancel anytime

  • ✓100+ physician-written reports
  • ✓EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Interim global phase 2 AZUR-1 results show durable responses with dostarlimab monotherapy in untreated MSI-H/dMMR stage II/III locally advanced rectal cancer
  • AI health chatbot shows no benefit for perinatal anxiety or depression
  • ADCE-D01 showed a 30% objective response rate in topline phase 1 results for previously treated advanced soft tissue sarcoma
License Content
Terms of Use | Disclaimer
Cookie Policy

Get the app

Read 2 Minute Medicine on iPhone, iPad and Android.

Download on the App StoreGet it on Google Play
QR code for www.2minutemedicine.com/app
On a computer? Scan this with your phone’s camera.
2MM+ All Access Full details →

The medical literature, distilled daily.

Monthly plan selected: $4.99 /month.

$4.99/month

3-day free trial · cancel anytime

Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

Yearly plan selected: $49.90 /year.

$49.90/year

2 months free

Start 3-day free trial

Then $49.90/year.

Membership benefits

  • ✓100+ new physician-written study summaries monthly, 12,000+ searchable
  • ✓AI EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
  • ✓FDA drug approvals + clinical calculators

Already a member? Sign in

  • Get the app
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • Medical Calculators
    • Clinical Guidelines
    • Physician Pay by Specialty
    • FDA Drug Approvals
    • RVU Search
    • ICD-10 Code Lookup
    • Drug Safety for Breastfeeding/Pregnancy
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
    • NPI Registry Lookup
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
No Result
View All Result

© 2026 2 Minute Medicine, Inc. - Physician-written medical news.